FrancophonIA/ELRC3.0 huggingface dataset:
English: Patients taking Prasugrel Mylan should also take aspirin as prescribed by their doctors.
Estonian: Ravimit Prasugrel Mylan kasutavad patsiendid peavad võtma ka arsti määratud annuses aspiriini.
English: Because Prasugrel Mylan is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Estonian: Et Prasugrel Mylan on geneeriline ravim ja võrdlusravimiga bioekvivalentne, peetakse tema kasulikkust ja riske samadeks mis võrdlusravimil.
English: It includes unstable angina (a severe type of chest pain) and heart attack.
Estonian: Need seisundid on näiteks ebastabiilne stenokardia (teatud tugev rindkerevalu) ja südameinfarkt.
English: This is then followed by 10 mg taken once a day, except in patients weighing less than 60 kg, who should take 5 mg once a day.
Estonian: Edaspidi võetakse ravimit Prasugrel Mylan 10 mg üks kord ööpäevas, v.a alla 60 kg patsiendid, kelle annus on 5 mg üks kord ööpäevas.
English: As for every medicine, the company provided studies on the quality of Prasugrel Mylan.
Estonian: Nagu iga ravimi korral, esitas ettevõte ravimi Prasugrel Mylan kvaliteedi uuringud.
English: Therefore, the Agency's view was that, as for Efient, the benefit of Prasugrel Mylan outweighs the identified risk and it can be authorised for use in the EU.
Estonian: Seetõttu on amet arvamusel, et nagu ka Efienti korral, ületab ravimi Prasugrel Mylan kasulikkus sellega kaasnevad riskid ja seda võib kasutada ELis.
English: The company that markets Prasugrel Mylan will make sure that educational materials are available for doctors who will treat patients with the medicine.
Estonian: Ravimi Prasugrel Mylan turustaja tagab teabematerjalid kõigile arstidele, kes hakkavad patsiente selle ravimiga ravima.
English: Acute coronary syndrome is a group of conditions in which blood supply in the vessels supplying the heart is interrupted so heart tissue cannot work properly or dies.
Estonian: Äge koronaarsündroom tähendab seisundeid, mille korral on südame verevarustus häiritud, mistõttu südamekude ei saa normaalselt toimida või kärbub.
English: Side effects reported with Prasugrel Mylan are carefully evaluated and any necessary action taken to protect patients.
Estonian: Ravimi Prasugrel Mylan kõrvalnähte hinnatakse hoolikalt ja patsientide kaitseks rakendatakse vajalikke meetmeid.
English: Percutaneous coronary intervention is a procedure used to unblock the blood vessels supplying the heart.
Estonian: Perkutaanne koronaarinterventsioon on protseduur, millega kõrvaldatakse südant verega varustavate veresoonte ummistus.
English: Prasugrel Mylan is available as tablets (5 and 10 mg) and can only be obtained with a prescription.
Estonian: Ravimit Prasugrel Mylan turustatakse tablettidena (5 mg ja 10 mg).
English: Prasugrel stops the platelets aggregating by blocking a substance called ADP from binding to a receptor (target) on their surface.
Estonian: Prasugreel peatab trombotsüütide agregatsiooni, blokeerides ADP seondumise retseptoriga trombotsüütide pinnal.
English: Prasugrel Mylan contains the active substance prasugrel and is a ‘generic medicine'.
Estonian: Prasugrel Mylan sisaldab toimeainena prasugreeli ja on geneeriline ravim.
English: As for all medicines, data on the use of Prasugrel Mylan are continuously monitored.
Estonian: Nagu kõigi ravimite puhul, teostatakse ravimi Prasugrel Mylan kasutamise kohta pidevat järelevalvet.
English: This stops the platelets becoming ‘sticky', reducing the risk of a blood clot forming and helping to prevent a heart attack or a stroke.
Estonian: See peatab trombotsüütide agregatsiooni ja vähendab trombiriski, mis aitab ennetada infarkti või insulti.
English: In this case, the patient should take 5 mg daily following a 60-mg starting dose.
Estonian: Sel juhul tuleb pärast 60 mg algannust jätkata ravi annusega 5 mg ööpäevas.
English: An overview of Prasugrel Mylan and why it is authorised in the EU
Estonian: Ülevaade ravimist Prasugrel Mylan ja ELis müügiloa väljastamise põhjendus
English: Prasugrel Mylan treatment starts with one 60-mg dose.
Estonian: Ravi ravimiga Prasugrel Mylan alustatakse ühe 60 mg annusega.
English: How does Prasugrel Mylan work?
Estonian: Kuidas Prasugrel Mylan toimib?
English: Blood clots are caused by special cells in the blood, the platelets, sticking together (aggregating).
Estonian: trombotsüütide ehk vereliistakute - agregatsiooni (kokkukleepumise) tõttu.
English: How is Prasugrel Mylan used?
Estonian: Kuidas ravimit Prasugrel Mylan kasutatakse?
English: Other information about Prasugrel Mylan
Estonian: Muu teave ravimi Prasugrel Mylan kohta
English: How has Prasugrel Mylan been studied?
Estonian: Kuidas ravimit Prasugrel Mylan uuriti?
English: Prasugrel Mylan received a marketing authorisation valid throughout the EU on 16 May 2018.
Estonian: Prasugrel Mylan (prasugreel)EMA/203583/2018
English: The active substance in Prasugrel Mylan, prasugrel, is an inhibitor of platelet aggregation.
Estonian: Ravimi Prasugrel Mylan toimeaine prasugreel on trombotsüütide agregatsiooni inhibiitor, mis aitab ennetada trombide (soonesiseste verehüüvete) tekkimist.
English: What are the benefits and risks of Prasugrel Mylan?
Estonian: Milles seisneb ravimi Prasugrel Mylan kasulikkus ja mis riskid ravimiga kaasnevad?
English: Content (concentration)
Estonian: Pakendi sisu (kontsentratsioo n)
English: The Reference Member State was Hungary and the Concerned Member States were Czech Republic, Estonia, Hungary, Lithuania, Latvia, Poland, Romania and Slovak Republic.
Estonian: Viiteliikmesriik oli Ungari ja asjaomased liikmesriigid olid Eesti, Leedu, Läti, Poola, Rumeenia, Slovaki Vabariik, Tšehhi Vabariik ja Ungari.
English: The Mutual Recognition Procedure started on 3 August 2007.
Estonian: Vastastikuse tunnustamise menetlus algas 2007. aasta 3. augustil.
English: A positive opinion was adopted by consensus on 24 July 2008.
Estonian: Positiivne arvamus võeti konsensuse alusel vastu 2008. aasta 24. juulil.
English: Concerns related to the formal proof of bioequivalence and the lack of a wide therapeutic experience which were considered a potential serious risk to public health.
Estonian: Probleemid olid seotud bioekvivalentsuse formaalse tõendamisega ja laialdase terapeutilise kogemuse puudumisega, mida peeti võimalikuks tõsiseks ohuks rahvatervisele.
English: These Member States were not able to reach an agreement in respect of the Mutual Recognition of the Marketing Authorisation granted by the Reference Member State.
Estonian: Kõnealused liikmesriigid ei jõudnud üksmeelele viiteliikmesriigi välja antud müügiloa vastastikuse tunnustamise osas.
English: The Rapporteur was Dr Ondřej Slanař (CZ) and Co-Rapporteur(s) was Prof János Borvendég (HU).
Estonian: Raportöör oli dr Ondřej Slanař (Tšehhi Vabariik) ja kaasraportöör oli professor János Borvendég (Ungari).
English: The Marketing Authorisation Holder provided written explanations on 2 June 2008.
Estonian: Müügiloa hoidja esitas kirjalikud selgitused 2008. aasta 2. juunil.
English: The arbitration procedure started on 21 February 2008 with the adoption of a list of questions.
Estonian: Vahekohtumenetlus algas 2008. aasta 21. veebruaril küsimuste loetelu kinnitamisega.
English: During their July 2008 meeting, the CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, was of the opinion that the benefit/risk ratio is favourable for Lisonorm, that the objections raised by Czech Republic and Latvia should not prevent the granting of a Marketing Authorisation.
Estonian: 2008. aasta juulis toimunud kohtumisel leidis inimravimite komitee, tuginedes kõigile esitatud andmetele ja komiteesisesele teaduslikule arutelule, et Lisonormi kasulikkuse ja riski suhe on soodne ning Tšehhi Vabariigi ja Läti tõstatatud vastuväited ei ole müügiloa andmisel takistuseks.
English: The Summary of Product Characteristics, Labelling and Package Leaflet of the Reference Member State should be amended.
Estonian: Viiteliikmesriigi esitatud ravimi omaduste kokkuvõtet, märgistust ja pakendi infolehte tuleb muuta.
English: Lisonorm tablet contains 5mg amlodipine/ 10mg lisinopril and is an anti-hypertensive indicated in patients with blood pressure adequately controlled with lisinopril and amlodipine given concurrently at the same dose level.
Estonian: Lisonormi tablett sisaldab 5 mg amlodipiini / 10 mg lisinopriili ja on vererõhku langetav (antihüpertensiivne) ravim, mis on näidustatud patsientidele, kellel vererõhu väärtused on lisinopriili ja amlodipiini samaaegse samade annustega ravi abil saadud küllaldase kontrolli alla.
English: The Czech Republic and Latvia referred the reasons for disagreement to the EMEA on 1 February 2008.
Estonian: Tšehhi Vabariik ja Läti esitasid eriarvamuse põhjused Euroopa Ravimiametile 2008. aasta 1. veebruaril.
English: Gedeon Richter Plc obtained a national marketing authorisation for Lisonorm which was authorised in Bulgaria on 29 December 2006, before Bulgaria joined the European Union.
Estonian: Gedeon Richter Plc-le anti Lisonormi riiklik müügiluba Bulgaarias 2006. aasta 29. detsembril enne Bulgaaria ühinemist Euroopa Liiduga.
English: The list of the product names concerned is given in Annex I. The scientific conclusions are provided in Annex II, together with the Summary of Product Characteristics in Annex III.
Estonian: Asjaomaste ravimite loetelu on esitatud I lisas, teaduslikud järeldused II lisas ning ravimi omaduste kokkuvõtte III lisas.
English: The final opinion was converted into a Decision by the European Commission on 12 November 2008.
Estonian: Euroopa Komisjon muutis lõpparvamuse otsuseks 2008. aasta 12. novembril.
English: COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) OPINION FOLLOWING AN ARTICLE 29(4)1 REFERRAL FOR Lisonorm and associated names International Non-Proprietary Name (INN): lisinopril + amlodipine
Estonian: INIMRAVIMITE KOMITEE ARVAMUS PÄRAST ARTIKLI 29 LÕIKE 41 KOHAST ESILDIST, MIS KÄSITLES RAVIMIT Lisonorm ja sarnased nimetused Rahvusvaheline mittekaubanduslik nimetus (INN): lisinopriil + amlodipiin
English: Gedeon Richter Plc submitted a Marketing Authorisation Application (MAA) via mutual recognition procedure for Lisonorm on the basis of the marketing authorisation granted by Hungary on 30 April 2004.
Estonian: Gedeon Richter Plc esitas Lisonormi müügiloa taotluse vastastikuse tunnustamise menetluse kaudu, tuginedes müügiloale, mille Ungari oli välja andnud 2004. aasta 30. aprillil.
English: 27 July 2010
Estonian: 27. juulil 2010
English: Opinion following an Article 34
Estonian: Arvamus pärast artikli 34
English: The final opinion was converted into a Decision by the European Commission on 27 July 2010.
Estonian: Lõplik arvamus kinnitati Euroopa Komisjoni otsusena 27. juulil 2010.
English: The target species are: pigs, chickens, turkeys and rabbits.
Estonian: Sihtliigid on sead, kanad, kalkunid ja küülikud.
English: 1 Article 34 of Directive 2001/82/EC
Estonian: 1 Direktiivi 2001/82/EÜ artikkel 34.
English: Oral explanations were given on 10 February 2010.
Estonian: Suulised selgitused anti 10. veebruaril 2010.
English: Written explanations were provided by the marketing authorisation holders on 20 April 2009 and 16 November 2009.
Estonian: Müügiloa hoidjad esitasid kirjalikud selgitused 20. aprillil 2009 ja 16. novembril 2009.
English: Tiamulin is a semi-synthetic antibiotic belonging to the pleuromutilin group of antibiotics and it is used only in veterinary medicine.
Estonian: Tiamuliin on pleuromutiliinide rühma kuuluv poolsünteetiline antibiootikum ja seda kasutatakse üksnes veterinaarravimites.
English: The referral procedure started on 15 October 2008.
Estonian: Esildist hakati menetlema 15. oktoobril 2008.
English: The rapporteur and co-rapporteur appointed were: Prof. Stane Srčič and Dr Karolina Törneke respectively.
Estonian: Hindajaks ja kaashindajaks määrati vastavalt prof. Stane Srčič ja dr. Karolina Törneke.
English: Tiamulin is used for the treatment and prevention of gastrointestinal and respiratory infections caused by different bacterial pathogens in pigs, poultry and rabbits.
Estonian: Tiamuliini kasutatakse mitmesuguste bakteriaalsete patogeenide põhjustatud seedetrakti ja hingamisteede infektsioonide raviks ja ennetamiseks sigadel, kodulindudel ja küülikutel.
English: referral for Tiamutin premix and associated names
Estonian: kohast esildist Tiamutini eelsegu ja seotud nimetuste kohta
English: Based on the rapporteurs' assessment of the currently available data, the CVMP adopted, on 10 March 2010, an opinion recommending the amendment of the marketing authorisations in terms of the summary of the product characteristics and labelling in order to harmonise the indications for use, amount to be administered and administration route and withdrawal periods.
Estonian: Hindajate koostatud praegu olemasolevate andmete hinnangu põhjal võttis veterinaarravimite komitee 10. märtsil 2010 vastu arvamuse, milles soovitas muuta müügilubades ravimi omaduste kokkuvõtet ja märgistust, et ühtlustada asjaomaste ravimite kasutamise näidustusi, annustatavaid koguseid, manustamisteed ja keeluaegu.
English: Premixes containing tiamulin are marketed across the European Union under a variety of invented names and the authorised premix formulations are based on tiamulin hydrogen fumarate in a variety of concentrations: 0.8%, 2%, 10% and 80%.
Estonian: Tiamuliini sisaldavaid eelsegusid turustatakse kogu Euroopas eri nimetustega ravimitena ning müügiloaga eelsegud põhinevad eri kontsentratsiooniga (0,8%, 2%, 10% ja 80%) tiamuliinvesinikfumaraadil.
English: The list of product names concerned is given in Annex I. The scientific conclusions are provided in Annex II, together with the amended summary of product characteristics and labelling in Annex III.
Estonian: Asjaomased raviminimetused on esitatud I lisas, teaduslikud järeldused II lisas ning muudetud ravimi omaduste kokkuvõte ja märgistus III lisas.
English: Due to differences among the nationally authorised summaries of product characteristics for Tiamutin premix and associated names across the European Union, especially as regards indications for use, amount to be administered and administration route and withdrawal periods, on 18 September 2008 Ireland and Belgium referred the matter to the European Medicines Agency under Article 34 of Directive 2001/82/EC.
Estonian: 18. septembril 2008 tegid Iirimaa ja Belgia Euroopa Ravimiametile direktiivi 2001/82/EÜ artikli 34 kohase esildise probleemi tõttu, et Tiamutini eelsegu ja seotud nimetuste liikmesriikide kinnitatud ravimi omaduste kokkuvõtted, eelkõige kasutuse näidustused, annustatavad kogused, manustamisteed ja keeluajad on kogu Euroopa Liidus erinevad.
English: What measures are being taken to ensure the safe and effective use of Yervoy?
Estonian: Mis meetmed võetakse, et tagada Yervoy ohutu ja efektiivne kasutamine?
English: Yervoy (ipilimumab)
Estonian: Yervoy (ipilimumaab)
English: Yervoy received a marketing authorisation valid throughout the EU on 13 July 2011.
Estonian: Yervoy on saanud müügiloa, mis kehtib kogu ELis, 13. juulil 2011.
English: This overview was last updated in 12-2018.
Estonian: Kokkuvõtte viimane uuendus: 12.2018.
English: What is Yervoy and what is it used for?
Estonian: Mis on Yervoy ja milleks seda kasutatakse?
English: Further information on Yervoy can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/Yervoy.
Estonian: Lisateave Yervoy kohta on ameti veebilehel: ema.europa.eu/medicines/human/EPAR/Yervoy.
English: Advanced melanoma
Estonian: Kaugelearenenud melanoom
English: The Agency decided that Yervoy's benefits are greater than its risks and it can be authorised for use in the EU.
Estonian: Euroopa Ravimiamet otsustas, et Yervoy kasulikkus on suurem kui sellega kaasnevad riskid ja et ravimi kasutamise võib ELis heaks kiita.
English: Because the medicine has been studied in very few adolescents, there is uncertainty about the medicine's side effects.
Estonian: Et ravimit on uuritud väga vähestel noorukitel, esineb teatud ebakindlus seoses ravimi kõrvalnähtudega.
English: As for all medicines, data on the use of Yervoy are continuously monitored.
Estonian: Nagu kõigi ravimite puhul, teostatakse Yervoy kasutamise kohta pidevat järelevalvet.
English: The effects of Yervoy in adolescents are expected to be similar to those in adults.
Estonian: Yervoy toime noorukitel eeldatavasti sarnaneb toimega täiskasvanutel.
English: Therefore, all adolescents treated with Yervoy will be monitored closely.
Estonian: Seepärast jälgitakse kõiki Yervoyd kasutavaid noorukeid hoolikalt.
English: However, about one-third of the patients could not complete Yervoy treatment due to side effects.
Estonian: Samas ei saanud ligikaudu kolmandik Yervoyd kasutanud patsientidest kõrvalnähtude tõttu teha Yervoy-ravi lõpuni.
English: However, patients treated with the higher dose had more side effects and were less likely to complete treatment as a result.
Estonian: Suuremat annust kasutanud patsientidel oli samas rohkem kõrvalnähte ja neil oli seetõttu väiksem tõenäosus teha ravi lõpuni.
English: The most frequent side effects of the medicine are mild to moderate in severity.
Estonian: Ravimi kõige sagedamad kõrvalnähud on kerged kuni mõõdukad.
English: Side effects reported with Yervoy are carefully evaluated and any necessary action taken to protect patients.
Estonian: Yervoy kõrvalnähte hinnatakse hoolikalt ja patsientide kaitseks rakendatakse vajalikke meetmeid.
English: Most will improve with appropriate treatment or on stopping Yervoy.
Estonian: Enamik kõrvalnähtudest möödub asjakohase raviga või pärast Yervoy-ravi lõpetamist.
English: For more information about using Yervoy, see the package leaflet or contact a doctor or pharmacist.
Estonian: Lisateavet Yervoy kasutamise kohta vt pakendi infolehest või konsulteeri oma arsti või apteekriga.
English: What are the risks associated with Yervoy?
Estonian: Mis riskid Yervoyga kaasnevad?
English: Yervoy is commonly associated with side effects resulting from excessive activity of the immune system, including severe reactions and inflammation.
Estonian: Yervoyd seostatakse sageli immuunsüsteemi liigsest aktiivsusest põhjustatud kõrvalnähtudega, sealhulgas raskete reaktsioonide ja põletikuga.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Yervoy have also been included in the summary of product characteristics and the package leaflet.
Estonian: Yervoy ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on samuti lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: As it is not clear how much Yervoy contributes to the benefits when given in combination with nivolumab in patients with advanced renal cell carcinoma, the company must conduct a study to determine the precise contribution of Yervoy and if the risks associated with Yervoy can be further minimised.
Estonian: Et ei ole teada, kui palju suurendab Yervoy ravi kasulikkust kasutamisel kombinatsioonis nivolumaabiga kaugelearenenud neerurakk-kartsinoomiga patsientidel, peab ettevõte tegema uuringu, et hinnata Yervoy täpset panust ja Yervoy riskide täiendava minimeerimise võimalikkust.
English: In addition, 41.6% of patients (177 out of 423) responded to the treatment with the combination compared with 26.5% (112 out of 416) of those receiving sunitinib.
Estonian: Kombinatsioonravile reageeris 41,6% patsientidest (177 patsienti 423st) ja sunitiniibravile 26,5% patsientidest (112 patsienti 416st).
English: The most common side effects (which may affect more than 1 in 10 people) are diarrhoea, rash, itching, tiredness, nausea (feeling sick), vomiting, decreased appetite and abdominal pain (belly ache).
Estonian: Kõige sagedamad kõrvalnähud (võivad esineda enam kui 1 patsiendil 10st) on kõhulahtisus, lööve, sügelus, väsimus, iiveldus, oksendamine, isutus ja kõhuvalu.
English: Several studies have shown that Yervoy is effective in prolonging the lives of patients with advanced melanoma.
Estonian: Mitu uuringut on tõendanud, et Yervoy on efektiivne kaugelearenenud melanoomiga patsientide elumuse pikendamisel.
English: The European Medicines Agency noted that Yervoy improves survival in melanoma, a condition where overall survival rates are low.
Estonian: Euroopa Ravimiamet märkis, et Yervoy suurendab elumust melanoomi korral, mille üldine elumus on väike.
English: Yervoy is usually used in combination with another medicine, nivolumab, but can also be used on its own for melanoma.
Estonian: Yervoyd kasutatakse tavaliselt koos teise ravimi, nivolumaabiga, kuid melanoomi korral tohib seda kasutada ka ainuravimina.
English: How is Yervoy used?
Estonian: Kuidas Yervoyd kasutatakse?
English: The results showed that in patients at moderate or high risk of their cancer getting worse, patients given the combination lived overall longer than those given sunitinib.
Estonian: Tulemused tõendasid, et vähi süvenemise mõõduka või suure riskiga patsientidest elasid kombinatsioonravi saanud patsiendid kokkuvõttes kauem kui sunitiniibi saanud patsiendid.
English: Yervoy is given by infusion (drip) into a vein over 90 minutes and the dose depends on the patient's body weight.
Estonian: Yerivoyd manustatakse 90 minutit kestva veeniinfusioonina ja annus sõltub patsiendi kehamassist.
English: The company that markets Yervoy must ensure that all healthcare professionals expected to prescribe the medicine as well as patients are given a brochure with safety information on the medicine including the side effects resulting from excessive activity of the immune system.
Estonian: Yervoy turustaja peab tagama, et kõik ravimit tõenäoliselt määravad meditsiinitöötajad ja patsiendid saavad brošüüri ravimi ohutu kasutamise teabega, sealhulgas immuunsüsteemi liigsest aktiivsusest põhjustatud kõrvalnähtude kohta.
English: Patients will also receive from their doctor an alert card summarising key safety information on the medicine.
Estonian: Samuti saavad patsiendid arstilt hoiatuskaardi Yervoy põhilise ohutusteabega.
English: A monoclonal antibody is a type of protein that has been designed to recognise and attach to a specific target in the body.
Estonian: Yervoy toimeaine ipilimumaab on monoklonaalne antikeha ehk teatud valk, mis on kavandatud ära tundma organismis olevat spetsiifilist sihtmärki ja sellega seonduma.
English: In the treatment of melanoma, despite longer survival with a dose of 10 mg per kg, the Agency recommended using Yervoy at a dose of 3 mg per kg because the higher dose caused more side effects and worsened patients' quality of life after the start of treatment.
Estonian: Kuigi elumus annusega 10 mg/kg oli pikem, soovitas amet kasutada Yervoy annust 3 mg/kg, sest suurem annus põhjustas ravi alustamise järel rohkem kõrvalnähte ja halvendas patsientide elukvaliteeti.
English: Because studies with Yervoy have included very few adolescents, the company has committed to collecting information on side effects, including any effects on growth and sexual maturation.
Estonian: Et Yervoy uuringutes on osalenud väga vähe noorukeid, kogub ettevõte kõrvalnähtude teavet, sealhulgas toime kohta kasvule ja sugulisele küpsemisele.
English: How does Yervoy work?
Estonian: Kuidas Yervoy toimib?
English: For renal cell carcinoma, Yervoy is given to patients who have not been treated before and are at moderate or high risk of their cancer getting worse.
Estonian: Neerurakk-kartsinoomi korral kasutatakse Yervoyd varem ravimata patsientidel, kelle vähi süvenemise risk on mõõdukas või suur.
English: After 24 months, 66.5% of patients given the combination were alive compared with 52.9% in the sunitinib group.
Estonian: 24 kuu pärast oli elus 66,5% kombinatsioonravi saanud patsientidest ja 52,9% sunitiniibi rühma patsientidest.
English: In two small studies involving a total of 30 adolescents aged 12 to 18 years with advanced melanoma, treatment with Yervoy produced similar levels of medicine in blood as in adults.
Estonian: Kahes väikses uuringus, milles osales kokku 30 kaugelearenenud melanoomiga 12-18-aastast noorukit, tekitas Yervoy-ravi noorukitel veres sarnase ravimisisalduse kui täiskasvanutel.